Eikon Therapeutics, Inc. Common Stock
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Roger Perlmutter
- Full Time Employees
- 384
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 230 Harriet Tubman Way Millbrae CA United States of America 94030
- IPO Date
- Feb 5, 2026
- CIK
- 0001861123
- Website
- eikontx.com
- Similar Companies
- Business
- Eikon Therapeutics, Inc. engages in drug discovery and development through an engineering-driven platform that tracks protein dynamics in living cells to accelerate identification of targeted therapies. It pursues a growing clinical pipeline focused on oncology with potential applications in immunology and neuroscience, complemented by preclinical programs across multiple therapeutic areas. Primary operations are based in the United States, with research and development activities centered in the San Francisco Bay Area corridor, and a broader geographic footprint that supports global collaboration with clinical trial sites and partners. The company was founded in 2019 and maintains its headquarters in Millbrae, California. Main products and services: proprietary discovery platform and instrumentation enabling real-time, molecular-resolution measurements of protein movement in living cells; integrated drug discovery pipeline including preclinical and clinical candidates across oncology, immunology, and neuroscience; early-stage research services and collaborations for target validation and mechanism-of-action studies; development of therapeutic candidates and associated translational research programs; partnerships with contract research organizations and academic institutions for assay development and translational biology validation. Latest major company changes: forms strategic partnerships and alliances to advance clinical programs and leverage external expertise in oncology and neuroscience; completes or secures funding rounds and potential strategic investments to support expansion of the pipeline and platform capabilities; announces new clinical or preclinical program milestones, including expansion into additional tumor indications and exploratory indications; undergoes organizational growth and potential governance or leadership changes to support increased pipeline execution and global clinical development activities; expands collaborations with biotechnology and pharmaceutical partners to accelerate discovery and access to novel targets. Industry context and segments: biotechnology and pharmaceutical development; internal discovery and early development services; clinical-stage oncology and neuroscience programs; platform technology enabling real-time imaging and measurement of molecular interactions in living cells; collaboration-based research and development models. Target markets and customers: global biopharma and life sciences customers seeking innovative oncology and neuroscience therapies; academic partners and contract research organizations supporting translational biology, assay development, and clinical program execution; patients with life-threatening cancers and neurological diseases through participating clinical trials. Geographic operations and subsidiaries: United States-based corporate and research operations with activities in California and related regional sites; collaborations and clinical trials across multiple countries as part of international development programs; no disclosed foreign subsidiaries beyond core R&D footprint. Founding year and headquarters: founded in 2019; headquartered in Millbrae, California, United States. Parent and subsidiary relations: operates as an independent biopharmaceutical company advancing its own pipeline; engages in strategic partnerships and collaboration agreements with external entities to support discovery, preclinical research, and clinical development.
Company News
Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress
Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer
Eikon Therapeutics, Inc. (EIKN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer
Eikon Therapeutics to Participate in Investor Conferences in September 2026
Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004
Eikon Therapeutics, Inc. (EIKN) Discusses Advances in PARP1 Biology and Next-Generation PARP Inhibitors in Oncology Transcript
Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald
Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board
Eikon Therapeutics, Inc.’s (NASDAQ:EIKN) Lock-Up Period Will Expire on August 4th
Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer
Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress
Eikon Therapeutics to Join the Russell 3000® Index
Eikon Therapeutics: Initiating Coverage With A Cautious Buy Rating
Eikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors
Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology
Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology
Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology
Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates